These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 26595362)
1. EFFICACY OF INTRAVITREAL INJECTION OF CONBERCEPT IN POLYPOIDAL CHOROIDAL VASCULOPATHY: Subgroup Analysis of the Aurora Study. Qu J; Cheng Y; Li X; Yu L; Ke X; Retina; 2016 May; 36(5):926-37. PubMed ID: 26595362 [TBL] [Abstract][Full Text] [Related]
2. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results. Kokame GT; Lai JC; Wee R; Yanagihara R; Shantha JG; Ayabe J; Hirai K BMC Ophthalmol; 2016 Jul; 16():127. PubMed ID: 27465105 [TBL] [Abstract][Full Text] [Related]
3. One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy. Yamamoto A; Okada AA; Kano M; Koizumi H; Saito M; Maruko I; Sekiryu T; Iida T Ophthalmology; 2015 Sep; 122(9):1866-72. PubMed ID: 26088619 [TBL] [Abstract][Full Text] [Related]
4. CORRELATION BETWEEN OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI AND VISUAL OUTCOMES AFTER ANTI-VEGF TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL VASCULOPATHY. Lee H; Ji B; Chung H; Kim HC Retina; 2016 Mar; 36(3):465-75. PubMed ID: 26076214 [TBL] [Abstract][Full Text] [Related]
5. Two-year outcomes of intravitreal conbercept therapy for polypoidal choroidal vasculopathy. Liu Y; Guo J; Tang W; Xu G; Liu W BMC Ophthalmol; 2024 Oct; 24(1):441. PubMed ID: 39379869 [TBL] [Abstract][Full Text] [Related]
6. Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection. Saito M; Kano M; Itagaki K; Ise S; Imaizumi K; Sekiryu T Jpn J Ophthalmol; 2016 Jan; 60(1):35-41. PubMed ID: 26350229 [TBL] [Abstract][Full Text] [Related]
7. ONE-YEAR RESULTS OF INTRAVITREAL AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY. Hara C; Sawa M; Sayanagi K; Nishida K Retina; 2016 Jan; 36(1):37-45. PubMed ID: 26383709 [TBL] [Abstract][Full Text] [Related]
8. Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy. Hosokawa M; Shiraga F; Yamashita A; Shiragami C; Ono A; Shirakata Y; Kimura S; Shiode Y; Kawata T; Hosogi M; Fujiwara A; Morizane Y Br J Ophthalmol; 2015 Aug; 99(8):1087-91. PubMed ID: 25712826 [TBL] [Abstract][Full Text] [Related]
9. AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY: As Needed Versus Fixed Interval Dosing. Inoue M; Yamane S; Taoka R; Arakawa A; Kadonosono K Retina; 2016 Aug; 36(8):1527-34. PubMed ID: 26710307 [TBL] [Abstract][Full Text] [Related]
10. Anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy with polyps resembling grape clusters. Lee JH; Lee WK Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):645-51. PubMed ID: 26138657 [TBL] [Abstract][Full Text] [Related]
11. INITIAL VERSUS DELAYED PHOTODYNAMIC THERAPY IN COMBINATION WITH RANIBIZUMAB FOR TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY: The Fujisan Study. Gomi F; Oshima Y; Mori R; Kano M; Saito M; Yamashita A; Iwata E; Maruko R; Retina; 2015 Aug; 35(8):1569-76. PubMed ID: 25830698 [TBL] [Abstract][Full Text] [Related]
12. Intravitreal ranibizumab for pigment epithelium detachment with subfoveal occult choroidal neovascularization: a prospective 24-month case series. Parodi MB; Iacono P; Papayannis A; Kontadakis SD; Cascavilla M; Pierro L; Gagliardi M; Bandello F Am J Ophthalmol; 2013 Jan; 155(1):103-108.e2. PubMed ID: 23022164 [TBL] [Abstract][Full Text] [Related]
13. Two-year course of subfoveal pigment epithelial detachment in eyes with age-related macular degeneration and visual acuity better than 20/40. Baba T; Kitahashi M; Kubota-Taniai M; Oshitari T; Yamamoto S Ophthalmologica; 2012; 228(2):102-9. PubMed ID: 22508168 [TBL] [Abstract][Full Text] [Related]
14. Intravitreal Anti-vascular Endothelial Growth Factor for Newly Diagnosed Symptomatic Polypoidal Choroidal Vasculopathy with Extrafoveal Polyps. Kim JH; Lee DW; Choi SC; Kim JW; Lee TG; Kim CG; Cho HJ Korean J Ophthalmol; 2015 Dec; 29(6):404-10. PubMed ID: 26635457 [TBL] [Abstract][Full Text] [Related]
15. ANGIOGRAPHIC FINDINGS OF RANIBIZUMAB-RESISTANT POLYPOIDAL CHOROIDAL VASCULOPATHY AFTER SWITCHING TO A TREAT-AND-EXTEND REGIMEN WITH INTRAVITREAL AFLIBERCEPT. Azuma K; Obata R; Nomura Y; Tan X; Takahashi H; Yanagi Y Retina; 2016 Nov; 36(11):2158-2165. PubMed ID: 27258669 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of intravitreal injection of conbercept for the treatment of patients with choroidal neovascularization secondary to pathological myopia: Results from the SHINY study. Gao L; Song Y; Sun X; Zhang J; Liu Y; Chen Y; Wu Z; Jian Y; Liu X; Lv L; Chen S; Wang YS; Chen N; Ke X; Zhang F Acta Ophthalmol; 2024 Jun; 102(4):e577-e586. PubMed ID: 38009430 [TBL] [Abstract][Full Text] [Related]
17. Short-term efficacy of intravitreal conbercept in treatment-naive patients with polypoidal choroidal vasculopathy. Peng Y; Zhang X; Li M; Liu B; Mi L; Zuo C; Wen F Drug Des Devel Ther; 2018; 12():339-345. PubMed ID: 29497280 [TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration. Ach T; Hoeh AE; Ruppenstein M; Kretz FT; Dithmar S Retina; 2010 Oct; 30(9):1420-5. PubMed ID: 20543764 [TBL] [Abstract][Full Text] [Related]
19. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy. Cho HJ; Baek JS; Lee DW; Cho SW; Kim CG; Kim JW Retina; 2013; 33(10):2126-32. PubMed ID: 23609123 [TBL] [Abstract][Full Text] [Related]
20. Resolution of persistent pigment epithelial detachment secondary to polypoidal choroidal vasculopathy in response to Aflibercept. Cheung CM; Mohla A; Wong TY Eye (Lond); 2014 Sep; 28(9):1148-9. PubMed ID: 24833182 [No Abstract] [Full Text] [Related] [Next] [New Search]